Table 1.
Clinical and biochemical parameters of the studied groups at baseline.
| Features | Italian type 1 AIH (57 patients) | Italian type 2 AIH (17 patients) | North American type 1 AIH (149 patients) |
| Gender (m/f) | 7/50 | 2/15 | 27/122 |
| Age (yr) | 38 (15–76) | 18 (8–34) | 47 (13–81) |
| AST (×UNL) | 10.9 (0.5–56) | 4.7 (1.5–5.1) | 9.5 (0.5–66) |
| ALP (×UNL) | 1.1 (0.2–4.56) | 1.5 (0.6–4.4) | 0.91 (0.6–6) |
| Bilirubin (mg/dL) | 1.3 (0.2–26) | 3.8 (0.9–4.3) | 1.9 (0.3–29) |
| Albumin (g/L) | 37 (24–46) | 40 (19–48) | 32 (15–42) |
| g-Globulin (g/L) | 23 (10–59) | 22 (13–48) | 29 (4–62) |
| IgG (mg/dL) | 2592 (1 260–6 948) | 2600 (1 530–4 212) | 2460 (248–7 200) |
| IgA (mg/dL) | 301 (40–963) | 346 (30–643) 2 | 90 (6–1 870) |
| IgM (mg/dL) | 200 (75–597) | 307 (150–577) | 228 (28–1 400) |
| ANA positivity | 34 (60%) | 0 | 113 (76%) |
| SMA positivity | 44 (77%) | 0 | 111 (74%) |
| LKM1 positivity | 0 | 16 (94%) | 0 |
| LC1 positivity | 0 | 4 (23%) | Not tested |
Data are shown as the median value (range). AST: serum aspartate aminotransferase level. ALP: serum alkaline phosphatase level. ANA: anti-nuclear antibodies. SMA: smooth muscle antibodies. LKM1: liver kidney microsome antibodies type 1. LC1: liver cytosol antibodies.